Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2
eBook - PDF

Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2

,
  1. 351 pages
  2. English
  3. PDF
  4. Available on iOS & Android
eBook - PDF

Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2

,

Trusted by 375,005 students

Access to over 1.5 million titles for a fair monthly price.

Study more efficiently using our study tools.

Information

Publisher
American Chemical Society
Year
2019
eBook ISBN
9780841234314
Print ISBN
9780841234314

Table of contents

  1. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2
  2. ACS Symposium Series1332
  3. Foreword
  4. Foreword
  5. Preface
  6. Synthetic Routes for Venetoclax at Different Stages of Development
  7. Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC
  8. From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib
  9. Discovery and Development of the First Antibody–Antibiotic Conjugate Linker-Drug
  10. The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis
  11. Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine
  12. The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain
  13. Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis
  14. Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)
  15. Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
  16. Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection
  17. Editors’ Biographies
  18. Indexes
  19. Author Index
  20. Subject Index
  21. Foreword
  22. Preface
  23. Synthetic Routes for Venetoclax at Different Stages of Development
  24. Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC
  25. From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib
  26. Discovery and Development of the First Antibody–Antibiotic Conjugate Linker-Drug
  27. The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis
  28. Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine
  29. The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain
  30. Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis
  31. Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)
  32. Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
  33. Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection
  34. Editors’ Biographies
  35. Indexes
  36. Author Index
  37. Subject Index